- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Amersham chair plans departure
Fourteen-year company veteran Richard Lapthorne will step down as Amersham chairman of the board May 7. Donald Brydon, who has been a nonexecutive director of Amersham for six years and is chair of the company's audit committee, will succeed him.
Fourteen-year company veteran Richard Lapthorne will step down as Amersham chairman of the board May 7. Donald Brydon, who has been a nonexecutive director of Amersham for six years and is chair of the company's audit committee, will succeed him. Lapthorne joined the Amersham board as a nonexecutive director in 1988. He served four years as chairman.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
